immunotherapybreast cancerlung cancerIL-12IL-15
…onstrating potential of enLIGHTEN™ to guide indication-specific immunotherapy development.…
7,227articles mentioning treatments
16,644treatment mentions
4,719distinct treatments extracted
0%of mentions human-reviewed
All extracted treatments
Showing 1,441–1,500 of 4,719, ordered by supporting articles. Choose a treatment to see its evidence.
Tumor irradiation1VTE prophylaxis1WBD1WM1aDSM1adjuvant TACE1advanced airway management1advanced migraine treatments1anti-TNFα1antidiabetic medications1antifungal treatment1brain biopsy1bronchodilator reversibility1cICB1cMDA1cMT1coil-only MMAE1conventional retreatment1curative-intent surgery1cytotoxic chemotherapies1dCBT1dcLVA1dental extraction1diathermy1digital mirror therapy1dual antithrombotic therapy1eCTG1eSCS1efSITT1excisional treatment1first-line aspiration1flow diverting embolization1glucose lowering therapies1gluten free diet1high-dose induction1home-based tDCS1human albumin infusion1intrathecal analgesia1irinotecan therapy1keratoprostheses1laparoscopic adrenalectomy1laparoscopic orchiopexy1laser1long-term dual antithrombotic therapy1maintenance dialysis1microsurgical fistulectomy1moderately emetogenic chemotherapy1modified Hotz procedure1multi-strain probiotics1nCIT1nCRT1non-surgical casting1particle embolization1platin-based chemotherapies1positive airway pressure therapy1premedication1pulse field ablation1radioligand therapy1sFIT1second antiplatelet therapy1
Articles mentioning treatments
7,227 articles · page 504 of 603chemotherapy-ICI combinationsVacV000PembrolizumabQMULOestrogen receptor-positive (ER+) breast cancer (BC)ICR Flow Cytometry FacilityBreast Cancer Now Histopathology Core Facilitybreast cancernivolumab
…n select high-risk, early-stage ER +/HER2−patients treated with chemotherapy-ICI combinations.1 2 Oncolytic viruses, with their dual ability to lyse tumour c…
adjuvant immunotherapyPrecision for MedicineLow-risk stage IB/IIA cutaneous melanomaAdvarra IRB
…mains at clinically relevant risk of recurrence and death while adjuvant immunotherapy is approved only for stages IIB-IV. The previously clinically v…
Bacteria-mediated cancer therapyOsteosarcomaShanghai Jiaotong University School of MedicineOS
…e immunosuppressive nature of the tumor microenvironment (TME). Bacteria-mediated cancer therapy (BMCT) has emerged as a promising strategy for solid tumors but…
combination therapymCRPCOlaparibSTAR0602prostate cancermSTAR1302NCT05592626IL-2
…ors, we assessed anti-tumor activity and survival benefit after combination therapy. To determine the requirement of a subset of immune cells (NK c…
immunotherapyrenal cell carcinomaRenal cell carcinoma (RCC)NeoGenomics Laboratories, Inc.
… While significant progress has been made in the development of immunotherapy for ccRCC, there are still many unanswered questions about the …
cell-based therapieslabetuzumabP601lungcolorectaltusamitamabNat Cancer 2021
…cally including antibodies, antibody-drug conjugates (ADC), and cell-based therapies, but none have been approved to date. We are developing a CEA-t…
chemotherapyThe Jackson LaboratoryNeo20Triple-negative breast cancerTNBCHouston Methodist Research Institute
…ecurrence and relapse rates among breast cancer subtypes. While chemotherapy, alone or in combination with immune checkpoint inhibitors, is …
endocrine therapyBreast cancerCDK4/6 inhibitorsCDK 4/6 inhibitorsXenoSTARTWorld Health OrganizationCDK4/6
… Despite advances such as CDK4/6 inhibitors in combination with endocrine therapy for hormone receptor-positive (HR+) breast cancer, therapeutic …
endocrine therapybreast cancerCDK4/6 inhibitorsCDK 4/6 inhibitorsXenoSTARTWorld Health OrganizationCDK4/6
… Despite advances such as CDK4/6 inhibitors in combination with endocrine therapy for hormone receptor-positive (HR+) breast cancer, therapeutic …
combination therapyGemPharmatechTA-1
…monstrated that TA-1 or anti-PD-1 inhibited tumor growth, while combination therapy led to greater tumor inhibition.Additionally, we established ad…
immunotherapyADU-S100GlioblastomaGBMSTING
…res the need for improved strategies. GBM remains refractory to immunotherapy, potentially due to its immunosuppressive tumor microenvironmen…